Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) announced that key data from a pharmacokinetic/safety study of M923, the Company’s lead biosimilar candidate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE